Natco Pharma Quarterly Results for Trading Insights
In Mar 2026, Natco Pharma (NATCOPHARM) reported revenue ₹817 Cr and net profit ₹269 Cr — revenue -36.5% YoY. Analyse Natco Pharma ownership structure to track promoter, FII and institutional holdings.
NATCOPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Natco Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View NATCOPHARM yearly price range for the annual high/low range and current price position.
- Revenue of ₹817 Cr in Mar 2026 (+2.9% vs Jun 2026, -36.5% vs Mar 2025)
- Net Profit of ₹269 Cr in Mar 2026 (+30.0% vs Jun 2026, -33.7% vs Mar 2025)
- EBITDA of ₹205 Cr in Mar 2026 (-16.7% vs Jun 2026)
- Operating Margin of 17.0% in Mar 2026 (-8.0pp vs Jun 2026)
- Earnings Per Share of ₹14.96 in Mar 2026 (+29.7% vs Jun 2026)
Natco Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NATCOPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 817 | 794 | 1,463 | 1,287 | 1,391 | 2.9% | -36.5% |
| Net Profit (₹ Cr) | 269 | 207 | 518 | 406 | 480 | - | - |
| EBITDA (₹ Cr) | 205 | 246 | 679 | 614 | 633 | - | - |
| EPS (₹) | 14.96 | 11.53 | 28.94 | 22.70 | 26.84 | - | - |
| Operating Margin (%) | 17.0% | 25.0% | 42.0% | 45.0% | 43.0% | - | - |
NATCOPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Natco Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Natco Pharma screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NATCOPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Natco Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores